MK-2206 dihydrochloride

Grouped product items
SizePrice Qty
5mg
$110.00
25mg
$385.00
Catalog Number : 1031320

description

MK-2206 is a highly allosteric selective Akt1,2,3 (IC50 5nM, 12nM, 65nM) inhibitor. It is reported to inhibit the proliferation of cancer cell lines when used synergistically with cytotoxic agents such as erlotinib or lapatinib and significantly enhances cell apoptosis.
product image

Additional Information

Applications:
FA
Synonyms:
MK2206, MK 2206, MK-2206 2HCl
Formulation:
Crystalline solid
Chemical Name:
8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride
Molecular Formula:

C25H21N5O 2HCl

Molecular Weight:
480.4
CAS Number
1032350-13-2
Purity:
≥98%
Storage Conditions:
Product should be kept at -20°C.
References:

Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., ... & Kotani, H. (2010). MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Molecular cancer therapeutics9(7), 1956-1967.

Cheng, Y., Zhang, Y., Zhang, L., Ren, X., Huber-Keener, K. J., Liu, X., ... & Rubin, E. (2012). MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Molecular cancer therapeutics11(1), 154-164.

Simioni, C., Neri, L. M., Tabellini, G., Ricci, F., Bressanin, D., Chiarini, F., ... & Pagliaro, P. (2012). Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia26(11), 2336-2342.

© BioGems International, Inc. All rights reserved.